Canton, MA, USA and Newark, DE, USA, April 8, 2020 - Abveris, Inc., a leader in contract research antibody discovery, today announced the extension of a strategic collaboration with ACROBiosystems, an internationally recognized manufacturer of recombinant proteins.

Under the terms of the agreement, the companies will leverage their core technologies to construct streamlined offerings to accelerate the pace of antibody discovery research.

By the terms of the agreement, over 1600 recombinant proteins for biologic drug discovery and development available in the ACROBiosystems catalog will be made available to Abveris customers to facilitate rapid initiation of antibody discovery projects.

"Our collaboration with ACROBiosystems is a highly valuable resource for Abveris and all of our partner companies,” commented Ryan Kelly, Director of Business Development at Abveris. "Our access to ACRO’s high-quality “off-the-shelf” reagents allows us to identify diverse, high affinity antibody clones in as little as one month total.”

“We are delighted to collaborate with Abveris, who shows their expertise in therapeutic antibody development. Their special DiversimAb^TM platform and single B cell screening platform speed up the antibody generation process while providing maximum diversity and affinity of the antibody candidates. It delivers additional benefits and comforts to scientists with using ACRO’s high-quality reagents and Abveris’s technologies as a combination,” commented Simin He, Marketing Manager of ACROBiosystems.

About Abveris: 

Abveris is a Boston-area specialty antibody discovery contract research organization located in Canton, Massachusetts, USA. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology. Additional information about Abveris is available at www.abveris.com.

About ACROBiosystems: 

ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application-oriented development strategy, with a particular focus on product design, quality control and solution-based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. Check out more details at: www.acrobiosystems.com/.

Contact for Abveris:

Ryan Kelly

Director of Business Development

rkelly@abveris.com

781-562-1170 x1002

Contact for ACROBiosystems:

Grace Wang

Marketing Specialist

Grace.wang@acrobiosystems.com

408-320-2195

Abveris, Inc. 

March 18, 2020

RE: Staying Open for Science, COVID Response

To Our Valued Customers & Partners,

The COVID outbreak has caused significant disruptions to the science community worldwide, and your ongoing antibody discovery projects shouldn’t cause additional stress. Abveris will remain open for business and continue to provide contract research services during the state of emergency even if a "shelter-in-place" order is called. 

Abveris has multiple ongoing projects that directly contribute to drug development efforts for underserved diseases and indications (including COVID-19 and multiple other viral agents). Our end-to-end antibody discovery services are fully operational and we’re accepting new hybridoma and B cell screening discovery projects. Are you delaying your discovery work because of COVID-related antigen production delays? We can help.

Schedule 15 minutes with us today to discuss your project.

We are closely monitoring communications from the Massachusetts State and Federal Governments regarding measures to prevent the spread of the virus. Abveris has implemented mandatory work-from-home policies for non-essential staff, and employee schedules have been adjusted to promote social distancing. 

We welcome you to lean on us during these turbulent times. As always, we look forward to supporting your science.

Sincerely,

Garren Hilow

CEO of Abveris

Adversity has the effect of eliciting talents,

which in prosperous circumstances would have lain dormant

- Horace

Updated 3/6/20: Event cancelled due to concerns surrounding spread of COVID-19 virus. 

A note from the event organizers:

Thank you for your interest in our event, and we apologize that we must postpone the happy hour indefinitely due to concerns surrounding the spread of Covid-19 infection. 

We're proud to announce that we had over 100 attendees registered a week ahead of the event. When the time is right, we will announce a revised event date. 

Thursday | March 12 | 5:00-7:30 PM | Cambridge, MA

Open Bar & Free Appetizers

What is Brews & Biopharma?

A free happy hour for biopharma scientists.

An exclusive, relaxed event for biopharma scientists in the protein sciences. Finish your workday (and start your night) with us over casual drinks, appetizers, and networking.

Who is invited?

Scientists from our partner companies and their invited guests*

*We kindly ask you not to invite your professional recruiter or salesperson friends as your guests. Nobody likes to be pitched after work. Thank you for respecting our policy. 

Abveris is excited to announce our new Green Initiatives blog series.

Why are we “green-ing” our operations?

We are a group of biopharmaceutical scientists advancing a scientific mission to produce better biotherapeutic drugs. While our mission does not directly relate to environmental science, we recognize that environmental health ties directly to human health. Global climate scientists have reached a clear consensus: to address climate change, dramatic action must be taken now. To ignore our company’s contribution to global carbon emissions and climate change is irresponsible.

What’s the plan?

Abveris is enacting sweeping changes to our laboratory and business operations to reduce our company's carbon footprint. Did you know that laboratory facilities use 5-10x more energy compared to similarly-sized “normal” office spaces? As our lab continues to grow, we're scrutinizing our policies on energy use and sustainability so we can build valuable therapeutic products without leaving a harmful footprint.

Why are we blogging about it?

In this blog series, you’ll find information about our efforts to overhaul our company operations and move towards net carbon-neutrality. These initiatives extend beyond our laboratory and office to build support for eco-conscious behaviors at work, at home, and in our supply chain. By showcasing what we are doing in our labs and offices, we hope that other pharmaceutical scientists can follow our progress and enact changes in their own companies and institutions.

In each of our posts, we’ll break down the following:

• What specific action are we taking to address climate change?
• Why are we making a change?
• What's the implementation strategy?
• How do we expect to make an impact?
• How can you, the reader, make a similar change in your own company?

Check out this blog series at abveris.com/greenscience to stay updated on our progress!

Date: January 29, 2019 at 10AM ET (7AM PT)

Please join FortéBio and Abveris for an exclusive webinar featuring Colby Souders, Chief Scientific Officer of Abveris, who will review ways to utilize Octet screening to streamline antibody discovery projects.

Who should attend:

• Antibody discovery scientists and researchers engaged in therapeutic drug discovery.
• Anyone interested in learning more about leveraging high-throughput Octet screening analyses to advance research and development.

Overview:

Integrating Octet into Early Antibody Discovery Workflows

Colby Souders, Chief Scientific Officer, Abveris

As industry-wide advancements in antibody drug discovery continue to push toward larger panels of candidates for early-stage characterization, more efficient identification of lead molecules through enhanced screening resolution is required. Integrating instruments like the Octet into the overall characterization workflow enables reliable, high throughput selection of lead candidates more effectively than alternative traditional techniques. This presentation will highlight a few unique methods of Octet utilization as a replacement or supplemental tool for various antibody discovery protocols. Comparisons across platforms, including traditional ELISA, flow cytometry, SPR, and in vivo studies will be presented.

December 9, 2019 – San Diego, CA - Are you attending the upcoming Antibody Engineering and Therapeutics conference in San Diego on December 9th? It’s not too late to sign up and spend some time in the sun while staying updated on the latest antibody discovery technologies and engineering techniques while networking with lead scientists in the antibody discovery world.

Join us on December 12 at noon for a scientific briefing led by Tracey Mullen, our Chief Operating Officer. Or, stop by our booth or posters in the exhibit hall and meet with Garren (CEO), Ryan (Director of Business Development) and Travis (Business Development Associate). See you there!

Click here to schedule an appointment with our team at the conference.

Information on our Scientific Briefing:

Scientific Briefing: Antibody Discovery for Traditionally Difficult Targets: in vivo, in vitro, or both?

Abstract: Leveraging the natural immune repertoire for antibody discovery has distinct advantages for positive downstream outcomes, including efficacy, developability and safety; however, traditional techniques typically fail to produce a productive response in situations where, for example, the target epitope has poor immunogenicity or is a rare, cryptic site. While some in vitro platforms can overcome these difficulties through careful guiding selection methods, significant downstream engineering is often required to ensure lead candidates harbor appropriate development qualities. Fortunately, recent advancements in protein engineering and antibody discovery have enabled improved drug development to these traditionally difficult targets. Using the AbX platform, the power of the immune system is harnessed to exemplify the breadth and comprehensive nature of the B cell repertoire. When applied to the most difficult target classes, lead candidates can be uncovered where traditional in vivo platforms typically fail, or significant engineering is required for in vitro discovery.

About the Antibody Engineering Conference: Antibody Engineering is the #1 antibody engineering conference for accelerating next-generation antibodies to commercial success. Find the latest science, technology, and partners in antibody engineering, immunobiology, and next-generation binders.

Visit News Medical today to view an interview with Tracey Mullen, Chief Operating Officer of Abveris, in the "Insights from Industry" interview series.

Date: December 4, 2019 at 11AM ET (8AM PT)

Please join Sartorius and Abveris for an exclusive webinar featuring Tracey Mullen, Chief Operating Officer of Abveris, who will review an antibody discovery campaign targeting a glycoprotein for induction of apoptosis. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt® iQue platform will be detailed.

Who should attend:

• Antibody discovery scientists and researchers engaged in therapeutic drug discovery for oncology indications.
• Anyone interested in learning more about leveraging high-throughput flow cytometry analysis to advance research and development.

Interested, but have a scheduling conflict? Click here to register and receive an on-demand link to watch later.

About the webinar:

The use of monoclonal antibody-based drugs has proven very successful to target and treat cancer with more than half of late-stage clinical trial antibodies carrying an oncology indication. By employing multiple final formats, unconjugated or conjugated antibodies capitalize on methods of cell killing spanning from direct targeting and inhibition of cell survival pathways to shuttling and delivery of cytotoxic drugs. Specific cell surface antigen recognition is paramount to the success of these drugs, necessitating high resolution early stage characterization of lead antibody drug candidates prior to preclinical development.

Major advancements in high-throughput flow cytometry have enabled more exquisite antibody discovery within the oncology field by providing thorough analysis of on-cell antigen specificity and function earlier in the drug discovery process. In this webinar, an antibody discovery campaign targeting a glycoprotein for induction of apoptosis will be reviewed. Methods for immunization, screening for lead antibody candidates and subsequent functional characterization through the use of the Intellicyt iQue platform will be detailed.

Date: November 13, 2019 at 2PM ET (11AM PT)

• Rapid reagent generation timelines
• Maximal epitope coverage with DiversimAb technology
• Highly sensitive specificity screening
• Identification of high-affinity mAbs
• Neutralizing and non-neutralizing mAbs
• Flexible deliverable strategies
• All work done in the USA

Interested, but have a scheduling conflict? Click here to register, and a video link will be sent after the webinar finishes. 

October 19, 2019 – Are you a team player looking for an exciting new challenge at a growing company? Visit our careers page today to learn about our open positions in our laboratory and business development teams.

Do you think you have the right attitude and the right experience to join our team, but the jobs we've posted don't look quite right for you? We welcome your application. Apply as an "antibody enthusiast" today!